Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8833987rdf:typepubmed:Citationlld:pubmed
pubmed-article:8833987lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:8833987lifeskim:mentionsumls-concept:C0330390lld:lifeskim
pubmed-article:8833987lifeskim:mentionsumls-concept:C0024117lld:lifeskim
pubmed-article:8833987lifeskim:mentionsumls-concept:C0162521lld:lifeskim
pubmed-article:8833987lifeskim:mentionsumls-concept:C0348016lld:lifeskim
pubmed-article:8833987lifeskim:mentionsumls-concept:C1272745lld:lifeskim
pubmed-article:8833987pubmed:issue1lld:pubmed
pubmed-article:8833987pubmed:dateCreated1996-12-3lld:pubmed
pubmed-article:8833987pubmed:abstractTextThe effects on exercise tolerance after acute administration of beta 2-agonists were investigated in 11 patients with partly reversible chronic airway obstruction after 400 micrograms of salbutamol (S) given intravenously (i.v.) and after 400 micrograms i.v. of a new selective beta 2-agonist, broxaterol (B), by a cardiopulmonary incremental exercise test. At rest, while VE increased in respect to basal conditions (C) after S (from 13.3 +/- 2.2 to 14.4 +/- 2.8 l/min; p < 0.05) and after B (from 13.6 +/- 3.1 to 15.5 +/- 3.6 l/min; p < 0.05), VO2, VCO2 and VO2/HR showed no substantial variations. A small, not significant reduction of PaO2 was observed both after S (from 82.7 +/- 11.7 to 79.1 +/- 16.7 mm Hg) and B (from 81.6 +/- 10.5 to 78.0 +/- 11.0 mm Hg). The maximum workload increased neither after S (from 67.5 +/- 39.1 to 66.6 +/- 37.0 W) nor after B (from 65.7 +/- 39.3 to 60.0 +/- 35.8 W). At peak of exercise, VO2, VCO2 and VO2/HR did not change after S and B as compared with C, whereas VE remained higher after both beta 2-agonists throughout the effort. VO2 at ventilatory anaerobic threshold (AT) was significantly greater either after S (from 744 +/- 378 to 815 +/- 302 ml/min; p < 0.05) and after B (from 756 +/- 290 to 842 +/- 292 ml/min; p < 0.05). The PaO2 increase shown by these patients during effort was greater after beta 2-agonists administration, delta PaO2 from rest to peak of exercise amounting to 14.9 +/- 14.3 vs. 7.8 +/- 8.2 mm Hg after S and to 17.8 +/- 15.1 vs. 8.8 +/- 10.9 mm Hg after B, in respect to relative baseline (p < 0.05). We conclude that beta 2-agonists, when given acutely, do not improve exercise tolerance in patients with reversible chronic airflow obstruction, although these drugs can induce a small increment of ventilatory AT. In addition, arterial blood gases do not deteriorate at rest and are better preserved during exercise after beta 2-agonists.lld:pubmed
pubmed-article:8833987pubmed:languageenglld:pubmed
pubmed-article:8833987pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8833987pubmed:citationSubsetIMlld:pubmed
pubmed-article:8833987pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8833987pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8833987pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8833987pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8833987pubmed:statusMEDLINElld:pubmed
pubmed-article:8833987pubmed:issn0025-7931lld:pubmed
pubmed-article:8833987pubmed:authorpubmed-author:GrassiVVlld:pubmed
pubmed-article:8833987pubmed:authorpubmed-author:BonaMMlld:pubmed
pubmed-article:8833987pubmed:authorpubmed-author:FilippiBBlld:pubmed
pubmed-article:8833987pubmed:authorpubmed-author:RomagnoniGGlld:pubmed
pubmed-article:8833987pubmed:authorpubmed-author:MalerbaMMlld:pubmed
pubmed-article:8833987pubmed:authorpubmed-author:TantucciCClld:pubmed
pubmed-article:8833987pubmed:issnTypePrintlld:pubmed
pubmed-article:8833987pubmed:volume63lld:pubmed
pubmed-article:8833987pubmed:ownerNLMlld:pubmed
pubmed-article:8833987pubmed:authorsCompleteYlld:pubmed
pubmed-article:8833987pubmed:pagination8-16lld:pubmed
pubmed-article:8833987pubmed:dateRevised2009-11-11lld:pubmed
pubmed-article:8833987pubmed:meshHeadingpubmed-meshheading:8833987-...lld:pubmed
pubmed-article:8833987pubmed:meshHeadingpubmed-meshheading:8833987-...lld:pubmed
pubmed-article:8833987pubmed:meshHeadingpubmed-meshheading:8833987-...lld:pubmed
pubmed-article:8833987pubmed:meshHeadingpubmed-meshheading:8833987-...lld:pubmed
pubmed-article:8833987pubmed:meshHeadingpubmed-meshheading:8833987-...lld:pubmed
pubmed-article:8833987pubmed:meshHeadingpubmed-meshheading:8833987-...lld:pubmed
pubmed-article:8833987pubmed:meshHeadingpubmed-meshheading:8833987-...lld:pubmed
pubmed-article:8833987pubmed:meshHeadingpubmed-meshheading:8833987-...lld:pubmed
pubmed-article:8833987pubmed:meshHeadingpubmed-meshheading:8833987-...lld:pubmed
pubmed-article:8833987pubmed:meshHeadingpubmed-meshheading:8833987-...lld:pubmed
pubmed-article:8833987pubmed:meshHeadingpubmed-meshheading:8833987-...lld:pubmed
pubmed-article:8833987pubmed:meshHeadingpubmed-meshheading:8833987-...lld:pubmed
pubmed-article:8833987pubmed:meshHeadingpubmed-meshheading:8833987-...lld:pubmed
pubmed-article:8833987pubmed:meshHeadingpubmed-meshheading:8833987-...lld:pubmed
pubmed-article:8833987pubmed:meshHeadingpubmed-meshheading:8833987-...lld:pubmed
pubmed-article:8833987pubmed:meshHeadingpubmed-meshheading:8833987-...lld:pubmed
pubmed-article:8833987pubmed:year1996lld:pubmed
pubmed-article:8833987pubmed:articleTitleIneffectiveness of intravenous beta 2-agonists on improving exercise tolerance in patients with reversible chronic airway obstruction.lld:pubmed
pubmed-article:8833987pubmed:affiliationClinica di Medicina Interna I, University of Brescia, Italy.lld:pubmed
pubmed-article:8833987pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8833987pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:8833987pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:8833987pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8833987lld:pubmed